2017 Festival of Biologics: World Biosimilar Congress USA
May 23, 2017

Axinn partner Stacie Ropka moderated a panel at the 2017 World Biosimilar Congress USA in San Diego. During "The Value of Certainty in the Biosimilar Regulatory Environment: Informed Thinking on Global Regulations and the IP Environment," panelists discussed which BPCIA uncertainties are causing the greatest hurdles; what we can expect in the next one to two years; whether the EMA and FDA are aligned in their thinking; how the ongoing patent dance litigation will help or hurt entry into the market and if a Supreme Court ruling will sort everything out. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.